The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

Official title: The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk

Summary: A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: * 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin * 60 patients treated with GLP-1 agonist as a second step after metformin * 60 patients treated with SGLT2 inhibitor as a second step after metformin * 60 patients treated with a combination of insulin and other antidiabetic agents (metformin - DPP4 inhibitors) Individuals will be equal distributed as far as age, gender and body mass index concerned. In addition, patients suffered from kidney disease and retinopathy are excluded.

Conditions: Diabetes Mellitus, Type 2

Keywords: Endothelial glycocalyx integrity, Oxidative stress biomarkers, Arterial stiffness, GLS, NT-proBNP, GDF-15, MOTS-c

Study type: OBSERVATIONAL

Enrollment: 240 (ESTIMATED)

Status: RECRUITING

Completion: 2027-06-30 (ESTIMATED)